Company intelligence / Profile preview

Pharmasset Inc.

Princeton, New Jersey, United Statespharmasset.com ↗

Ownership: Private
Employees: ~200
Development stage: Other

Overview

Pharmasset was a clinical-stage pharmaceutical company focused on developing oral antiviral therapeutics for hepatitis C. Its lead compound, PSI‑7977, showed strong efficacy and safety in Phase II studies and entered multiple Phase III trials targeting different HCV genotypes. The company also had additional nucleotide analogs in its pipeline for HCV and partnered with Roche on mericitabine. Gilead acquired Pharmasset to accelerate the development of all‑oral regimens for HCV treatment[1][6][7].

Therapeutic areas: Infectious Diseases
Modalities: small molecules (nucleoside/nucleotide analogs)
Industry: Biotech

Partnerships

Roche – co-development of mericitabine/RG7128[7].

Beyond the preview

Go deeper on Pharmasset Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharmasset Inc..